1. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Issue 8 (August 2021) Authors: Lynch, Ryan C; Cassaday, Ryan D; Smith, Stephen D; Fromm, Jonathan R; Cowan, Andrew J; Warren, Edus H; Shadman, Mazyar S; Shustov, Andrei; Till, Brian G; Ujjani, Chaitra S; Libby, Edward N; Philip, Mary; Coye, Hilary; Martino, Christen N; Bhark, Sandra L; Morris, Karolyn; Rasmussen, Heather; Behn... Journal: Lancet Issue: Volume 8:Issue 8(2021) Page Start: e562 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗